翰森制药:口服GLP-1授权MSD BD战略再下一城

中金公司
26 Dec 2024

公司近况2024 年12 月18 日,公司公告授予默沙东HS-10535(口服GLP-1 受体激动剂)全球独家许可协议。评论与MSD达成GLP-1 合作,交易总额超20 亿美元。根据该协议,默沙东获得开发、生产和商业化HS-10535 的全球独家许可权;公司将获得1.12 亿美元首付款,最高19 亿美元里程碑付款和基于产品销售的特许权使用费。在特定条件下,公司可能会在中国共同推广或独家商业化HS-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10